Randi Melissa Schuster1, Ailish Hanly2, Jodi Gilman3, Alan Budney4, Ryan Vandrey5, A Eden Evins3. 1. Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital (MGH) Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: rschuster@mgh.harvard.edu. 2. Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital (MGH) Boston, MA, USA. 3. Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital (MGH) Boston, MA, USA; Harvard Medical School, Boston, MA, USA. 4. Dartmouth College, Geisel School Of Medicine, Lebanon NH, USA. 5. Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: Rates of young adult cannabis use are rising, perceived harm is at its historical nadir, and most users do not want to quit. Most studies evaluating effects of cannabis use in young adults are cross-sectional, limiting causal inference. A method to reliably induce abstinence periods in cannabis users would allow assessment of the effects of abstinence and resumption of use on a variety of outcomes in a within-subjects, repeated measures design. METHODS: We examined the efficacy and feasibility of a voucher-based contingency management procedure for incentivizing one month of continuous cannabis abstinence among young adults who reported at least weekly cannabis use, volunteered to participate in a laboratory study, and did not express a desire to discontinue cannabis use long-term. Continuous cannabis abstinence was reinforced with an escalating incentive schedule, and self-report of abstinence was confirmed by frequent quantitative assays of urine cannabis metabolite (THCCOOH) concentration. New cannabis use during the abstinence period was determined using an established algorithm of change in creatinine-adjusted cannabis metabolite concentrations between study visits. RESULTS: Thirty-eight young adults, aged 18-25 years, enrolled and 34 (89.5%) attained biochemically confirmed 30-day abstinence. Among those who attained abstinence, 93.9% resumed regular use within two-weeks of incentive discontinuation. CONCLUSION: Findings support the feasibility and efficacy of contingency management to elicit short-term, continuous cannabis abstinence among young adult, non-treatment seeking, regular cannabis users. Further work should test the effectiveness of this contingency management procedure for cannabis abstinence in periods longer than one month, which may be required to evaluate some effects of abstinence.
BACKGROUND: Rates of young adult cannabis use are rising, perceived harm is at its historical nadir, and most users do not want to quit. Most studies evaluating effects of cannabis use in young adults are cross-sectional, limiting causal inference. A method to reliably induce abstinence periods in cannabis users would allow assessment of the effects of abstinence and resumption of use on a variety of outcomes in a within-subjects, repeated measures design. METHODS: We examined the efficacy and feasibility of a voucher-based contingency management procedure for incentivizing one month of continuous cannabis abstinence among young adults who reported at least weekly cannabis use, volunteered to participate in a laboratory study, and did not express a desire to discontinue cannabis use long-term. Continuous cannabis abstinence was reinforced with an escalating incentive schedule, and self-report of abstinence was confirmed by frequent quantitative assays of urine cannabis metabolite (THCCOOH) concentration. New cannabis use during the abstinence period was determined using an established algorithm of change in creatinine-adjusted cannabis metabolite concentrations between study visits. RESULTS: Thirty-eight young adults, aged 18-25 years, enrolled and 34 (89.5%) attained biochemically confirmed 30-day abstinence. Among those who attained abstinence, 93.9% resumed regular use within two-weeks of incentive discontinuation. CONCLUSION: Findings support the feasibility and efficacy of contingency management to elicit short-term, continuous cannabis abstinence among young adult, non-treatment seeking, regular cannabis users. Further work should test the effectiveness of this contingency management procedure for cannabis abstinence in periods longer than one month, which may be required to evaluate some effects of abstinence.
Authors: J N Giedd; J Blumenthal; N O Jeffries; F X Castellanos; H Liu; A Zijdenbos; T Paus; A C Evans; J L Rapoport Journal: Nat Neurosci Date: 1999-10 Impact factor: 24.884
Authors: Suchitra Krishnan-Sarin; Dana A Cavallo; Judith L Cooney; Ty S Schepis; Grace Kong; Thomas B Liss; Amanda K Liss; Thomas J McMahon; Charla Nich; Theresa Babuscio; Bruce J Rounsaville; Kathleen M Carroll Journal: Drug Alcohol Depend Date: 2013-03-22 Impact factor: 4.492
Authors: Ross H Lowe; Tsadik T Abraham; William D Darwin; Ronald Herning; Jean Lud Cadet; Marilyn A Huestis Journal: Drug Alcohol Depend Date: 2009-07-23 Impact factor: 4.492
Authors: Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall Journal: Nat Rev Dis Primers Date: 2021-02-25 Impact factor: 52.329
Authors: Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain Journal: Drug Alcohol Depend Date: 2020-04-26 Impact factor: 4.492
Authors: Randi Melissa Schuster; Kevin Potter; Ryan Vandrey; Maya Hareli; Jodi Gilman; David Schoenfeld; A Eden Evins Journal: J Psychopharmacol Date: 2019-09-19 Impact factor: 4.153
Authors: Megan E Cooke; Jodi M Gilman; Erin Lamberth; Natali Rychik; Brenden Tervo-Clemmens; A Eden Evins; Randi M Schuster Journal: Front Psychiatry Date: 2021-07-01 Impact factor: 4.157
Authors: Joanna Jacobus; Lindsay M Squeglia; Silvia Escobar; Benjamin M McKenna; Margie Mejia Hernandez; Kara S Bagot; Charles T Taylor; Marilyn A Huestis Journal: Psychopharmacology (Berl) Date: 2017-09-12 Impact factor: 4.530